MSFT 419.78 0.4234% AAPL 225.36 0.5039% NVDA 149.123 2.6594% GOOGL 180.02 -0.183% GOOG 181.75 -0.1209% AMZN 206.566 -0.1325% META 583.0 -0.0292% AVGO 176.035 -1.607% TSLA 339.0599 -3.1257% TSM 191.05 -1.546% LLY 813.99 -2.2164% V 308.82 -0.4866% JPM 239.89 0.2507% UNH 615.58 -1.5466% NVO 105.956 -2.8729% WMT 84.965 0.8966% LVMUY 120.91 -5.0793% XOM 120.78 0.2573% LVMHF 605.0 -5.1263% MA 529.85 -0.0509%
Last update at 2024-11-12T16:52:00Z
Regeneron announces three-year data for EYLEA HD Injection 8 mg study
Sat 19 Oct 24, 09:10 PMRegeneron price target lowered to $1,137 from $1,200 at Truist
Thu 17 Oct 24, 11:40 AMKodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
Thu 10 Oct 24, 02:05 PMRegeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Thu 10 Oct 24, 01:35 PMRegeneron Gains 13.5% Year to date: How to Play the Stock?
Tue 08 Oct 24, 06:17 PMRegeneron Pharmaceuticals, Inc. (REGN): A Buzzing AI Health Stock to Add to Your Portfolio
Sat 05 Oct 24, 12:43 PMShould You Buy the Dip on This Top Growth Stock?
Sat 05 Oct 24, 10:30 AMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 4858.80M | 9325.80M | 3810.40M | 2429.10M | 2553.50M |
Minority interest | - | - | - | - | - |
Net income | 4338.40M | 8075.30M | 3513.20M | 2115.80M | 2444.40M |
Selling general administrative | 2115.90M | 1824.90M | 1346.00M | 1834.80M | 1556.20M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 10612.50M | 13634.20M | 7377.20M | 7081.20M | 6276.70M |
Reconciled depreciation | 341.40M | 286.20M | 235.90M | 210.30M | 148.20M |
Ebit | 4738.90M | 8946.80M | 3576.60M | 1999.50M | 2386.20M |
Ebitda | 5173.30M | 9383.10M | 3867.30M | 2209.80M | 2534.40M |
Depreciation and amortization | 434.40M | 436.30M | 290.70M | 210.30M | 148.20M |
Non operating income net other | 179.30M | 436.30M | 290.70M | 249.50M | 47.30M |
Operating income | 4738.90M | 8946.80M | 3576.60M | 2209.80M | 2534.40M |
Other operating expenses | 7178.90M | 7124.90M | 4920.50M | 5653.60M | 4176.40M |
Interest expense | 59.40M | 57.30M | 56.90M | 30.20M | 28.20M |
Tax provision | 520.40M | 1250.50M | 297.20M | 313.30M | 109.10M |
Interest income | 160.10M | - | - | 88.10M | 13.70M |
Net interest income | 100.70M | -57.30000M | -56.90000M | -30.20000M | -28.20000M |
Extraordinary items | - | - | - | - | 68.00M |
Non recurring | 255.10M | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 520.40M | 1250.50M | 297.20M | 313.30M | 109.10M |
Total revenue | 12172.90M | 16071.70M | 8497.10M | 7863.40M | 6710.80M |
Total operating expenses | 5618.50M | 4687.40M | 3800.60M | 4871.40M | 3742.30M |
Cost of revenue | 1560.40M | 2437.50M | 1119.90M | 782.20M | 434.10M |
Total other income expense net | 119.90M | 379.00M | 233.80M | 219.30M | 19.10M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 4338.40M | 8075.30M | 3513.20M | 2115.80M | 2444.40M |
Net income applicable to common shares | 4338.40M | 8075.30M | 3513.20M | 2115.80M | 2444.40M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 33080.20M | 29214.50M | 25434.80M | 17163.30M | 14805.20M |
Intangible assets | 1038.60M | 915.50M | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 386.60M | 933.00M | 332.40M | 1164.00M | 959.30M |
Total liab | 7107.10M | 6550.50M | 6666.00M | 6138.00M | 3715.50M |
Total stockholder equity | 25973.10M | 22664.00M | 18768.80M | 11025.30M | 11089.70M |